代谢分析市场 - 全球产业规模、份额、趋势、机会及预测（按产品类型、应用、技术、最终用途、地区和竞争格局划分，2021-2031年）

全球代谢检测市场预计将从 2025 年的 17.1 亿美元成长到 2031 年的 27.2 亿美元，复合年增长率达到 8.02%。

这些检测方法用于测量代谢活性，例如酶动力学和代谢物浓度，是评估细胞生物能量学和生理健康的重要定量分析程序。该市场的主要成长要素是慢性代谢疾病盛行率的不断上升，以及由此带来的药物研发投入的增加，旨在开发新的治疗方法。根据世界肥胖联盟2024年的预测，到2035年，肥胖成年人的数量预计将达到15.3亿，凸显了对有效代谢筛检工具的迫切需求。这也推动了对用于治疗代谢症候群的药物研发中可靠方法的需求。

儘管市场成长前景良好，但由于先进检测技术高成本且技术复杂，仍面临许多障碍。多重分析仪和试剂需要大量资金投入和专业人员，这限制了预算有限的小规模实验室和学术机构的应用。这种经济障碍，加上复杂代谢组学数据解读的难度，阻碍了这些检测方法在资源匮乏地区的广泛应用，减缓了全球市场的整体扩张。

市场驱动因素

全球慢性代谢疾病（尤其是糖尿病）盛行率的快速成长是代谢检测市场的主要驱动力。随着患者数量的增加，製药公司和学术研究人员正优先开发针对代谢路径的治疗方法，从而增加了对标靶检验和先导化合物优化的检测应用。需要长期血糖控制管理的人群数量不断增加，也推动了这一趋势，从而对精准的诊断和监测工具产生了持续的需求。根据发表在2024年11月《柳叶刀》杂誌上题为「全球糖尿病盛行率不平等」的分析报告，全球成年糖尿病患者人数将达到8.28亿，这一数字迫切需要快速扩展代谢筛检能力。

此外，製药和生技公司不断增加的研发投入正在推动市场扩张，因为相关人员希望从盈利的抗肥胖和糖尿病治疗领域获利。各公司正大力投资高通量筛检和代谢谱分析，以识别新的生物标记和候选治疗药物，而这需要先进的检测平台。例如，礼来公司在其2024年2月发布的2023年度报告中披露，其研发支出增加至93.1亿美元，主要得益于对代谢功能障碍治疗药物的后期研发投入。这项投资与整个产业的趋势相符，即监管部门的核准会刺激对检测技术的再投资。美国食品药物管理局（FDA）在2024年核准了55种新分子实体（NME），与上年度相比有所增加，这创造了一个高度依赖代谢数据的创新环境。

市场挑战

先进检测技术固有的高昂成本和技术复杂性，对全球代谢检测市场的成长构成了重大障碍。这些定量分析程序所需的精密多重分析设备和试剂需要大量的资金投入，直接限制了其在成本敏感型环境中的应用。小规模研究机构和学术机构对于市场渗透至关重要，但它们往往缺乏购买和维护此类昂贵基础设施的财力。此外，解读复杂代谢组学数据需要专业人员，这造成了技能缺口，进一步限制了这些检测方法在发展中地区的应用。

这种资金和技术上的垄断阻碍了市场成长，因为高通量筛检工具的使用权主要集中在财力雄厚的大型製药公司手中，限制了其在更广泛的科学界的普及应用。这些资金限制的影响在近期的投资趋势中显而易见：根据马萨诸塞州生物技术委员会（MassBio）的数据，2025年上半年当地生物製药公司的创业投资金额较2024年同期下降了17.1%。资金短缺加剧了这项挑战，迫使实验室推迟升级到先进的检测平台，直接减缓了全球市场的收入成长。

市场趋势

人工智慧驱动的数据分析的整合正在从根本上改变全球代谢检测市场，它消除了代谢谱分析中复杂数据解读的瓶颈。现代检测方法产生的高维度资料集需要先进的机器学习演算法来检测传统统计方法常常忽略的细微生物标记模式。这项技术的整合加速了先导化合物的识别，并提高了代谢反应预测的准确性，从而提升了药物研发工作流程的效率。根据英伟达 (NVIDIA) 于 2025 年 7 月开展的「医疗保健和生命科学领域人工智慧现状：2025 年趋势」调查，超过 80% 的医疗保健和生命科学专业人士表示，他们的机构因采用人工智慧而获得了收入成长，这证实了这些运算工具的商业性和营运价值。

同时，晶片器官和3D培养模型的出现标誌着药物研发正朝着更贴近生理实际的测试环境迈进，从而减少对动物模型的依赖。动物模型往往无法准确预测药物对人体的代谢毒性。这些微生理系统能够模拟人体组织的动态生化微环境，从而更准确地评估药物代谢和生物能量学。製造商正在加速采用将这些模型与自动化技术结合的整合平台，以支援工业规模的筛检。例如，《药物发现新闻》（Drug Discovery News）在2025年10月报道，CN Bio宣布推出其「PhysioMimix Core」系统。该系统是一个一体化的晶片器官平台，能够同时对多达288个样本进行高通量筛检，展现了扩充性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球代谢分析市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（检测试剂盒/试剂、仪器/分析设备）
  • 透过应用（诊断（糖尿病、肥胖、癌症、心血管疾病等）、研究）
  • 依技术（比色分析、萤光分析、光谱分析）
  • 按最终用户（医院、诊断检查室、製药和生物製药公司、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美代谢分析市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲代谢分析市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区代谢分析市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲代谢分析市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲代谢分析市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球代谢分析市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Abcam Limited
• Agilent Technologies, Inc.
• Promega Corporation
• Kaneka Eurogentec SA
• RayBiotech Life, Inc.
• Sartorius AG
• Elabscience Bionovation Inc.
• BMG LABTECH GmbH

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Metabolism Assays Market is projected to expand from USD 1.71 Billion in 2025 to USD 2.72 Billion by 2031, achieving a compound annual growth rate of 8.02%. These assays serve as quantitative analytical procedures essential for measuring metabolic activities, such as enzyme kinetics and metabolite concentrations, to evaluate cellular bioenergetics and physiological health. The market is primarily driven by the rising prevalence of chronic metabolic disorders and the consequent intensification of pharmaceutical research and development efforts aimed at creating novel therapeutic interventions. According to the World Obesity Federation's 2024 projections, the number of adults living with obesity is expected to reach 1.53 billion by 2035, highlighting the critical need for effective metabolic screening tools and fueling the demand for robust methods in drug discovery to treat metabolic syndromes.

Despite this positive growth outlook, the market encounters significant obstacles due to the high costs and technical complexities associated with advanced assay technologies. Multiplexing instruments and reagents necessitate substantial capital investment and specialized personnel, which restricts their adoption in smaller research laboratories and academic institutions with limited budgets. This financial hurdle, combined with the difficulty of interpreting complex metabolomic data, hampers the widespread implementation of these assays in resource-constrained regions, thereby slowing the overall expansion of the global market.

Market Driver

The surging global prevalence of chronic metabolic diseases, particularly diabetes, acts as the primary catalyst for the metabolism assays market. As patient populations grow, pharmaceutical companies and academic researchers are prioritizing the development of therapeutics that target metabolic pathways, leading to increased usage of assays for target validation and lead optimization. This trend is underscored by the rising number of individuals requiring long-term glucose regulation management, creating a continuous demand for precise diagnostic and monitoring tools. According to an analysis in The Lancet from November 2024, titled 'Global inequalities in diabetes prevalence', the global number of adults living with diabetes has reached 828 million, a figure that necessitates the rapid scaling of metabolic screening capabilities.

Furthermore, increasing research and development investment by pharmaceutical and biotechnology firms reinforces market expansion as stakeholders aim to capitalize on the lucrative anti-obesity and diabetes drug sectors. Companies are channeling significant capital into high-throughput screening and metabolic profiling to identify novel biomarkers and therapeutic candidates, which requires advanced assay platforms. For instance, Eli Lilly and Company reported in their February 2024 '2023 Annual Report' that research and development expenses rose to $9.31 billion, largely driven by late-stage investments in metabolic dysfunction treatments. This financial commitment aligns with broader industry trends where regulatory success drives reinvestment in assay technologies, as evidenced by the U.S. Food and Drug Administration's confirmation in 2024 of 55 novel molecular entity approvals in the preceding year, reflecting an innovation environment heavily dependent on metabolic data.

Market Challenge

The substantial cost and technical complexity inherent in advanced assay technologies present a significant barrier to the growth of the Global Metabolism Assays Market. Advanced multiplexing instruments and the necessary reagents for these quantitative analytical procedures require major capital expenditure, which directly limits their adoption in cost-sensitive environments. Smaller research laboratories and academic institutions, which are essential for broad market penetration, often lack the financial resources to procure and maintain such expensive infrastructure. Additionally, the need for specialized personnel to interpret complex metabolomic data results in a skills gap that further restricts the deployment of these assays in developing regions.

This financial and technical exclusivity hinders market growth by limiting the use of high-throughput screening tools primarily to well-funded pharmaceutical giants, thereby suppressing volume growth across the wider scientific community. The impact of these financial constraints is highlighted by recent investment trends; according to the Massachusetts Biotechnology Council (MassBio), venture capital investments in regional biopharmaceutical companies declined by 17.1% in the first half of 2025 compared to the same period in 2024. This contraction in available funding exacerbates the challenge, compelling laboratories to delay upgrades to advanced assay platforms and directly decelerating the revenue trajectory of the global market.

Market Trends

The integration of AI-driven data analytics is fundamentally transforming the Global Metabolism Assays Market by resolving the bottleneck of complex data interpretation in metabolic profiling. The high-dimensional datasets produced by modern assays demand advanced machine learning algorithms to detect subtle biomarker patterns that traditional statistical methods might overlook. This technological integration accelerates hit identification and improves the predictive accuracy of metabolic responses, thereby enhancing operational efficiency in drug discovery workflows. According to the 'State of AI in Healthcare and Life Sciences: 2025 Trends' survey by NVIDIA in July 2025, over 80% of healthcare and life sciences professionals indicated that AI adoption has increased revenue at their organizations, confirming the commercial and operational value of these computational tools.

Concurrently, the emergence of organ-on-a-chip and 3D culture models marks a significant shift toward physiologically relevant testing environments, reducing dependence on animal models that often fail to predict human metabolic toxicity. These microphysiological systems mimic the dynamic biochemical microenvironments of human tissues, enabling more accurate assessments of drug metabolism and bioenergetics. Manufacturers are increasingly introducing integrated platforms that combine these models with automation to support industrial-scale screening. For example, Drug Discovery News reported in October 2025 that CN Bio unveiled the PhysioMimix Core system, an all-in-one organ-on-a-chip platform capable of high-throughput screening for up to 288 samples simultaneously, demonstrating the scalability necessary for broader pharmaceutical adoption.

Key Market Players

• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Abcam Limited
• Agilent Technologies, Inc.
• Promega Corporation
• Kaneka Eurogentec S.A.
• RayBiotech Life, Inc.
• Sartorius AG
• Elabscience Bionovation Inc.
• BMG LABTECH GmbH

Report Scope

In this report, the Global Metabolism Assays Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolism Assays Market, By Product Type

• Assay Kits & Reagents
• Instruments & Analyzers

Metabolism Assays Market, By Application

• Diagnostics (Diabetes, Obesity, Cancer, Cardiovascular diseases, Other)
• Research

Metabolism Assays Market, By Technology

• Colorimetry
• Fluorimetry
• Spectrometry

Metabolism Assays Market, By End-use

• Hospitals
• Diagnostic Labs
• Pharmaceutical & biopharmaceutical companies
• Others

Metabolism Assays Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metabolism Assays Market.

Available Customizations:

Global Metabolism Assays Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metabolism Assays Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Assay Kits & Reagents, Instruments & Analyzers)
  • 5.2.2. By Application (Diagnostics (Diabetes, Obesity, Cancer, Cardiovascular diseases, Other), Research)
  • 5.2.3. By Technology (Colorimetry, Fluorimetry, Spectrometry)
  • 5.2.4. By End-use (Hospitals, Diagnostic Labs, Pharmaceutical & biopharmaceutical companies, others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Metabolism Assays Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Technology
  • 6.2.4. By End-use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metabolism Assays Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Technology
      • 6.3.1.2.4. By End-use
  • 6.3.2. Canada Metabolism Assays Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Technology
      • 6.3.2.2.4. By End-use
  • 6.3.3. Mexico Metabolism Assays Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Technology
      • 6.3.3.2.4. By End-use

7. Europe Metabolism Assays Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Technology
  • 7.2.4. By End-use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metabolism Assays Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technology
      • 7.3.1.2.4. By End-use
  • 7.3.2. France Metabolism Assays Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technology
      • 7.3.2.2.4. By End-use
  • 7.3.3. United Kingdom Metabolism Assays Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technology
      • 7.3.3.2.4. By End-use
  • 7.3.4. Italy Metabolism Assays Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Technology
      • 7.3.4.2.4. By End-use
  • 7.3.5. Spain Metabolism Assays Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Technology
      • 7.3.5.2.4. By End-use

8. Asia Pacific Metabolism Assays Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Technology
  • 8.2.4. By End-use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Metabolism Assays Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technology
      • 8.3.1.2.4. By End-use
  • 8.3.2. India Metabolism Assays Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technology
      • 8.3.2.2.4. By End-use
  • 8.3.3. Japan Metabolism Assays Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technology
      • 8.3.3.2.4. By End-use
  • 8.3.4. South Korea Metabolism Assays Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technology
      • 8.3.4.2.4. By End-use
  • 8.3.5. Australia Metabolism Assays Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technology
      • 8.3.5.2.4. By End-use

9. Middle East & Africa Metabolism Assays Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Technology
  • 9.2.4. By End-use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Metabolism Assays Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technology
      • 9.3.1.2.4. By End-use
  • 9.3.2. UAE Metabolism Assays Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technology
      • 9.3.2.2.4. By End-use
  • 9.3.3. South Africa Metabolism Assays Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technology
      • 9.3.3.2.4. By End-use

10. South America Metabolism Assays Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Technology
  • 10.2.4. By End-use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Metabolism Assays Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technology
      • 10.3.1.2.4. By End-use
  • 10.3.2. Colombia Metabolism Assays Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technology
      • 10.3.2.2.4. By End-use
  • 10.3.3. Argentina Metabolism Assays Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technology
      • 10.3.3.2.4. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Metabolism Assays Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Thermo Fisher Scientific, Inc.
• 15.3. Abcam Limited
• 15.4. Agilent Technologies, Inc.
• 15.5. Promega Corporation
• 15.6. Kaneka Eurogentec S.A.
• 15.7. RayBiotech Life, Inc.
• 15.8. Sartorius AG
• 15.9. Elabscience Bionovation Inc.
• 15.10. BMG LABTECH GmbH

16. Strategic Recommendations

17. About Us & Disclaimer